MyChoice[®]CDx

Myriad HRD Companion Diagnostic Test

Test Request Form To avoid delays please complete entire form

I<mark>\/</mark>Iyriad genetics

Myriad Genetic Laboratories Inc. 322 North 2200 West • Salt Lake City, UT 84116 Toll-Free (877) 283-6709 • Fax (801) 883-8998 mychoicecdx@myriad.com

÷

1. Patient information (Complete information required)

Legal name (last)	Legal name (first)		(m.i.)	Sex at birt	th	Birthdate (r	nm/dd/yyyy)	Patie	ent ID #
				Πм	F				
Email (this enables us to contact the patient if there is an issue wit	h their order or sample)	Cell phone					Daytime phone		
	I don't have the patient's email								
Address				City				State	Zip

2. Ordering provider information (Only name and HCP Account # required unless you're a new customer or HCP # is unknown)

Name (last)	Name (first)		Myriad HCP account #	Degree	NPI #		
Address			City			State	Zip
Office contact name	Phone	Fax		Email			

3. Clinical information

Ovarian cancer (Select primary diagnosis): Left ovary Right ovary Left fallopian tube Right fallopian tube Peritoneum (cul-de-sac, mesentery, mesocolon, omentum, parietal, pelvic)	Age at diagnosis:	Date of biopsy or surgery: (mm/dd/yyyy)	For Medicare Patients Only:	At the time of biopsy or surgery: Hospital outpatient Non-hospital patient Hospital inpatient (>24 hour stay) Discharge date:(mm/dd/yyyy)		
(Check if applicable to patient) 🗖 Bone marrow transplant recipient Type: 🗋 Autologous 📑 Allogeneic (If allogeneic please call 800-469-7423 x3850)						

4. Test requested

Myriad MyChoice® CDx - Next generation sequencing-based in vitro diagnostic test that assesses the qualitative detection and classification of single nucleotide variants, insertions and deletions, and large rearrangement variants in protein coding regions and intron/exon boundaries of the BRCA1 and BRCA2 genes and the determination of Genomic Instability Score (GIS) which is an algorithmic measurement of Loss of Heterozygosity (LOH), Telomeric Allelic Imbalance (TAI), and Large-scale State Transitions (LST) using DNA isolated from formalin-fixed paraffin embedded (FFPE) tumor tissue specimens. The results of the test are used as an aid in identifying ovarian cancer patients with positive homologous recombination deficiency (HRD) status, who are eligible, because of a positive test result for deleterious or suspected deleterious mutations in BRCA1 or BRCA2 genes, or may become eligible, because of a positive test result for deleterious or suspected deleterious mutations in BRCA1 or BRCA2 genes or a positive Genomic Instability Score, for treatment with the approved targeted therapy for Lynparza® (olaparib). In addition, detection of deleterious or suspected deleterious BRCA1 and BRCA2 mutations and/or positive Genomic Instability Score in ovarian cancer patients is also associated with enhanced progression-free survival (PFS) from Zejula® (niraparib) maintenance therapy in accordance with the most recently approved therapeutic product labeling. *When GIS is unable to be analyzed, tumor mutation BRCA1/2 status alone may be reported.

5. Specimen information

# of block(s):	# of slide(s):	Tissue type submitted (e.g., ovary):		
Clinical stage: 🔲 I		Date specimen retrieved from archive: (mm/dd/yyyy)		
Clinical status:	Recurrent Metastatic Relapsed Refractory Other	Specimen Identification Number		
Sample fixative:	Fixed tissue	as it appears on the tissue block(s) or		
(check one):	Other (describe):	slides submitted to Myriad Genetics:		

6 Specimen retrieval

I want Myriad Genetic Laboratories, Inc. to request the specimen. (Complete the information below.)							
Location of specimen	Phone	Fax	Contact name				
7. Authorized signature							
I hereby authorize testing and confirm that informed consent has been obtained, if required by state law. I hereby attest that the person listed in the ordering physician space above is authorized by law in the relevant jurisdiction							
to order the test(s) requested herein.	ne test(s) requested herein.		Date				
8. Billing/payment information							
Option 1: Please bill insurance (For Medicare patients: only available if test order date is more than two weeks after discharge date.) Include enlarged copies of both sides of insurance card(s). If two cards are submitted, indicate which is primary.							
Option 2: Uninsured (please call Customer Service for questions regarding test prices or for credit card payment.)							

Option 3: Other billing (To establish an account, submit billing information with this form.)

□ Bill our institutional account #:

and other jurisdictions. ©2024, Myriad Genetics, Inc.

or established research project code #:

or authorization / voucher #:

Myriad, MyChoice CDx, and their logos are either trademarks or registered trademarks of Myriad Genetics, Inc., in the United States MyChoice CDx TRF/11-22 | PRD-0751 Rev 11



Important information for patient

Billing terms: I represent that I am covered by insurance and authorize Myriad Genetic Laboratories, Inc. (MGL) to give my designated insurance carrier, health plan, or third party administrator (collectively "Plan") the relevant health information necessary for reimbursement. I authorize Plan benefits to be payable to MGL. I understand MGL will contact me if I will be financially responsible for any non-covered service. By agreeing to testing I also authorize Myriad to obtain a consumer credit report on me from a consumer reporting agency selected by Myriad. I understand and agree that Myriad may use my consumer credit report to confirm whether my income qualifies me for financial assistance. I further understand that this is not a credit application and will not impact my credit score. I agree to assist MGL in resolving insurance claim issues and if I don't assist, I may be responsible for the full test cost. I permit a copy of this authorization to be used in place of the original.

^Translation of Billing Terms are available in Mandarin and Spanish at www. myriadpromise.com. Myriad also provides free language services to people whose primary language is not English through qualified interpreters. If you need these services, contact Customer Service at 800-469-7423.

Affordability: Myriad Promise™

- The majority of appropriate patients pay \$0
- Myriad will work with your insurance provider to help you get the appropriate coverage
- Myriad is committed to provide patients with access to accurate and affordable genetic results
- For more information please refer to the billing information at www.myriadpromise.com

Non-discrimination: Federal law (GINA) and laws in most states prohibit discrimination regarding employment eligibility, health benefits, or health insurance premiums based solely on genetic information. Myriad Genetic Laboratories, Inc. (Myriad) complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex.

Sex assigned at birth is a label given to an individual at birth, typically "male" or "female".

A legal name identifies a person for legal and administrative purposes. It is recorded on a birth certificate, marriage certificate, or other government issued document that records a name change.